Baxter International Inc. · NYSE:BAX
Baxter International — Shareholder Meeting (May 2018)
23 slides from Baxter International's shareholder meeting presentation, May 8, 2018
Slide 1: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders May 8, 2018
Slide 2: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders ? Introductions 2018 Annual Baxter Voting Questions Adjournment and Meeting Meeting Overview Results and Procedures Proposals Answers | 2
Slide 3: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders May 8, 2018
Slide 4: Baxter's Board of Directors
Baxter’s Board of Directors José (Joe) E. Thomas T. Thomas F. Chen John D. Forsyth James R. Gavin III, Peter S. Hellman Almeida Stallkamp M.D., Ph.D. Munib Islam Michael F. Mahoney Stephen N. Carole J. Shapazian Cathy R. Smith Albert P.L. Oesterle, M.D. Stroucken All Directors up for reelection at t
Slide 5: Baxter's Senior Leadership Team
Baxter’s Senior Leadership Team Giuseppe Accogli David Ferguson, Ph.D. Ellen McIntosh SVP and President, Global Businesses GM, Medication Delivery SVP, Corporate Secretary Laura Angelini Cristiano Franzi Scott Pleau GM, Renal Care SVP and President, Europe, Middle East, Africa SVP, Operations Scott
Slide 6: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning the company’s financial results, business development activities, capital structure, cost savings initiatives, and R&D pipeline including results of clinical trials and planned product launches. The statements are
Slide 7: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders May 8, 2018
Slide 8: 2018 Annual Meeting Proposals
2018 Annual Meeting Proposals PROPOSAL PROPOSAL PROPOSAL PROPOSAL PROPOSAL 1 2 3 4 5 Election of Advisory Vote to Ratification of Independent Right to Act Directors Approve Named Independent Board Chairman by Written Executive Registered Consent Officer Public Compensation Accounting Firm | 8
Slide 9: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders May 8, 2018
Slide 10: Delivering on our Mission
Delivering on our Mission | 10
Slide 11: Baxter Profile
Baxter Profile 2017 Revenue By Region By Business Industry-Leading Portfolio Global Presence Continuous $10.6B Americas 54% Renal Care 33% EMEA 26% Medication Delivery 26% Innovation Global Asia Pacific 20% Pharmaceuticals 18% Net Sales Nutrition 8% Advanced Surgery 7% Acute Therapies 4% Operational
Slide 12: Full-Year 2017 Financial Snapshot
Full-Year 2017 Financial Snapshot Global Reported Adjusted Adjusted Earnings Free Cash Revenues Operating Margin per Diluted Share Flow3 (Restated)2 +5% +250 +27% +35% Operational Growth1 Basis Points $2.48 $1.2B $10.6B 16.3% 13.8% $1.96 $905M $10.2B 2016 2017 2016 2017 2016 2017 2016 2017 See www.b
Slide 13: Focused on Achieving Sustained Top Quartile Performance
Focused on Achieving Sustained Top Quartile Performance Quality and Best place Industry-leading patient safety to work performance Drive improved performance to deliver optimal results for patients, customers, stockholders and employees | 13
Slide 14: Quality and Patient Safety
Quality and Patient Safety Investing in quality systems and processes to help ensure the highest standards Demonstrating strong progress on key quality metrics ‒ Positive performance in Medical Device Reports, Field Alert Reports, Conversions ‒ Warning letters closed in Irvine, Round Lake Parent
Slide 15: Best Place to Work
Best Place to Work Baxter’s inclusive culture and diverse workforce help advance our mission and fuel innovation Recognized by 2018 Women’s Choice Award The Voice of Women Baxter manufacturing facility, Cuernavaca, Mexico | 15
Slide 16: Best Place to Work: Commitment to the Community
Best Place to Work: Commitment to the Community Baxter is making a difference in our communities by supporting increased access to care, disaster relief, STEM education, and other efforts We drive sustainability throughout our operations Recognized by Hurricane Maria disaster relief, Puerto Rico
Slide 17: Industry-Leading Performance
Industry-Leading Performance Portfolio and Operational Capital Innovation Excellence Allocation Management | 17
Slide 18: Industry-Leading Performance: Portfolio and Innovation Management
Industry-Leading Performance Portfolio and Innovation Management Shifting greater R&D investment to new product development Executed on robust pipeline with more than 50 launches1 in 2017 Accelerating portfolio and pipeline through collaborations with Mayo Clinic, Ramot at Tel Aviv University/
Slide 19: Industry-Leading Performance: Operational Excellence
Industry-Leading Performance Operational Excellence Transforming cost structure, eliminating waste and increasing efficiency Optimizing organizational structure to drive improved performance Simplifying portfolio and optimizing manufacturing footprint Baxter R&D facility, Alliance Park, Belgiu
Slide 20: Industry-Leading Performance: Capital Allocation
Industry-Leading Performance Capital Allocation Just announced a 19% increase to the dividend this morning ─ Represents a 65% increase from post-Baxalta spin-off dividend rate1 Executed selective share repurchases Investing in growth through acquisitions of Claris Injectables, Wound Care Techn
Slide 21: Delivering Significant Value for Investors
Delivering Significant Value for Investors *Partial Month of May 1Source: Bloomberg | 21
Slide 22: Continuing Strong Momentum in 2018 and Beyond
Continuing Strong Momentum in 2018 and Beyond ► Increasing innovation to drive accelerated revenue growth ► Maintaining strong cadence of product launches and geographic expansions ► Realizing ongoing benefits of cost reduction initiatives and organization optimization ► Strategically deploying capi
Slide 23: 2018 Annual Meeting of Stockholders
2018 Annual Meeting of Stockholders May 8, 2018
Baxter International — Shareholder Meeting (May 2018) on 6ix